Medocriptine (Bromocriptine)

Bromocriptine is a selective dopamine D2 receptor agonist. By activating these receptors in the pituitary gland it suppresses prolactin secretion, and in the central nervous system it enhances dopaminergic pathways that control movement and growth hormone release, addressing the underlying mechanisms of its approved indications.

The specific dose of Medocriptine is determined by the prescribing clinician based on the patient’s diagnosis, severity, renal and hepatic function, and response to therapy. Dosage regimens may differ for hyperprolactinemia, Parkinson's disease, or acromegaly, and should follow the prescriber’s instructions.

Safety data for bromocriptine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Medocriptine product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Bromocriptine is an ergot‑derived dopamine agonist, whereas newer non‑ergot agents such as cabergoline have longer half‑lives and may have a different side‑effect profile. Choice of therapy depends on clinical response, tolerability, comorbid conditions, and physician preference.

Medocriptine should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat, and direct sunlight to maintain stability and potency throughout its shelf life.

Medocriptine is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed unless otherwise directed by a healthcare professional. Dosing times may be adjusted to reduce gastrointestinal side effects.

Serious adverse events include valvular heart disease, pulmonary fibrosis, severe hypotension, psychosis, seizures, and hepatic toxicity. Patients should be monitored regularly for cardiovascular symptoms, respiratory changes, mental status alterations, and liver function abnormalities.

Medocriptine is contraindicated in patients with known hypersensitivity to bromocriptine or other ergot derivatives, uncontrolled hypertension, active cardiac valvulopathy, or severe hepatic impairment. Caution is also advised for individuals with a history of psychiatric disorders or seizure disorders.